Loretta J. Nastoupil, MD: Partway through your treatment I changed things. I changed the IV rituximab to subcutaneous rituximab, something they call Hycela. What was your experience with that? Whitney ...
May 10, 2007 (Las Vegas) — Rituximab can be safely infused using a rapid 90-minute protocol in patients with non-Hodgkin's lymphoma, according to a presentation made at the annual meeting of the ...
Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen Receptor ...
Primary Mediastinal Large B-Cell Lymphoma: A Clinicopathologic Study of 43 Patients From the Nebraska Lymphoma Study Group PURPOSE: Rituximab was recently approved for use in relapsed, low-grade ...
THOUSAND OAKS, Calif., June 6, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® ...
A study of patients with pemphigus who were in remission after a rituximab cycle found that administering an additional infusion at month 6, when guided by relapse predictors, significantly improved ...
Please provide your email address to receive an email when new articles are posted on . The timing of rituximab infusion or cumulative lifetime rituximab dose did not appear statistically ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE™ (rituximab-pvvr), a biosimilar to Rituxan ® ...
Rituximab and mycophenolate mofetil are used to treat pemphigus vulgaris, but they have not been adequately compared in clinical trials. In a randomized, controlled trial, we assigned patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback